Japan biotechnology market was valued at $32.1 billion in 2025 and is projected to reach $59.5 billion by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). The growth of the market is driven by a strong regulatory environment, government-backed initiatives, and a focus on innovation in healthcare, pharmaceutical, and industrial biotechnology industries. The Ministries of Economy, Trade and Industry (METI) and Health, Labour and Welfare (MHLW) support a favorable investment climate for R&D that supports investment in precision medicine, regenerative therapies, and green bio-manufacturing.
Browse the full report description of “Japan Biotechnology Market Size, Share & Trends Analysis Report by Product (Instruments & Equipment, Reagents & Consumables, and Software & Services), by Technology (DNA Sequencing & Genomics, Cell Culture Technology, Nano biotechnology, Fermentation Technology, Chromatography & Separation, Tissue Engineering & Regenerative Medicine, CRISPR & Gene Editing, Proteomics & Protein Engineering, Bioinformatics, and Others) and by Application (Healthcare & Medical, Agriculture & Food, Industrial / Environmental and Marine Biotechnology), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/japan-biotechnology-market
According to the Statistics Bureau of Japan in 2023, R&D funds spent in the three areas positioned by the Japanese government as fundamental technologies to be strategically addressed were 272.5 billion yen ($1.9 billion) for AI, 385.0 billion yen ($2.7 billion) for biotechnology, and 132.2 billion yen ($0.2 billion) for Quantum technology. This, in comparison to the previous fiscal year, reflects a 56.3% increase in AI, a 55.1% increase in Biotechnology, and a 13.2% increase in Quantum technology. AI and Biotechnology have increased significantly.
Consumer and market behavior in Japan demonstrates a twofold trend: established pharmaceutical and healthcare providers increasingly demand advanced biologics and precision therapies, while growing consumer interest is seen in nutraceuticals, bio-based ingredients, and environmentally sustainable biotech applications.
Key Market Players and Their Innovations
- Regional industry leaders such as Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd, Fujifilm Holdings Corp., and Chugai Pharmaceutical Co., Ltd. are maintaining strong market positions. These players have strategies focusing on regenerative medicine, individualized healthcare, and collaborations with international biotech innovators.
- For instance, Fujifilm Holdings Corp. has used its market knowledge in regenerative medicine and bioprocessing to enhance its cell culture media and advanced therapy manufacturing solutions, aiding growth in stem cell and gene therapy applications.
- Furthermore, Takeda Pharmaceutical Company Ltd. has a significant pipeline in biopharma with indications in oncology, rare diseases, and gastroenterology, and invests further into new modalities of gene and cell therapies and developing digital platforms for drug discovery.
Key Market Developments
- In August 2025, ENHERTU (trastuzumab deruxtecan) was approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) unresectable or recurrent breast cancer. ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and is being developed and commercialized by Daiichi Sankyo in Japan.
- In July 2025, Krystal Biotech, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) granted marketing authorization to VYJUVEK (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB), starting from birth. VYJUVEK is the gene therapy providing medicine approved in Japan for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Product
- By Technology
- By Application
- Competitive Landscape - Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline K.K., Qiagen K.K., and Thermo Fisher Scientific Inc., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Japan Biotechnology Market Report Segment
By Product
- Instruments & Equipment
- Reagents & Consumables
- Software & Services
By Technology
- DNA Sequencing & Genomics
- Cell Culture Technology
- Nano biotechnology
- Fermentation Technology
- Chromatography & Separation
- Tissue Engineering & Regenerative Medicine
- CRISPR & Gene Editing
- Proteomics & Protein Engineering
- Bioinformatics
- Others
By Application
- Healthcare & Medical
- Agriculture & Food
- Industrial / Environmental
- Marine Biotechnology
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-biotechnology-market